13.87

1.09% 0.15

Oric Pharmaceuticals Inc (ORIC)

Overview News Price History Option Chain Financials Discussions Forecast

Oric Pharmaceuticals Inc stock is traded at $13.87, with a volume of 828.50K. It is up +1.09% in the last 24 hours and up +31.47% over the past month. ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Previous Close:

$13.72

Open:

$13.63

24h Volume:

828.50K

Relative Volume:

0.49

Market Cap:

$1.44B

Revenue:

Net Income/Loss:

$-135.21M

P/E Ratio:

-9.6918

EPS:

-1.4311

Net Cash Flow:

$-114.35M

1W Performance:

+2.74%

1M Performance:

+31.47%

6M Performance:

+38.84%

1Y Performance:

+39.68%

1-Day Range:

$13.40

$13.90

1-Week Range:

$13.12

$14.12

52-Week Range:

$7.23

$14.93

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name

Oric Pharmaceuticals Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(650) 388-5600

Address

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Employee

104

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

ORIC's Discussions on Twitter

Compare ORIC vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORIC Oric Pharmaceuticals Inc	13.87	1.43B	0	-135.21M	-114.35M	-1.4311
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-12-26	Resumed	Stifel	Buy
May-15-26	Upgrade	Goldman	Neutral → Buy
Jan-07-26	Initiated	Piper Sandler	Overweight
Nov-20-25	Initiated	Evercore ISI	Outperform
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-04-25	Resumed	Guggenheim	Buy
Jul-08-25	Initiated	Ladenburg Thalmann	Buy
Oct-31-24	Initiated	Wells Fargo	Overweight
Sep-06-24	Initiated	Stifel	Buy
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-21	Upgrade	Citigroup	Neutral → Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Aug-13-20	Initiated	Robert W. Baird	Outperform
Aug-06-20	Upgrade	Citigroup	Neutral → Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Citigroup	Neutral
May-19-20	Initiated	Guggenheim	Buy
May-19-20	Initiated	JP Morgan	Overweight
May-19-20	Initiated	Jefferies	Buy

View All

Oric Pharmaceuticals Inc Stock (ORIC) Latest News

Aug 13, 2026

ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits

Aug 13, 2026

Aug 12, 2026

ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25 - Bitget

Aug 10, 2026

ORIC Maintained by HC Wainwright & Co. -- Price Target Raised to $27 - GuruFocus

Aug 10, 2026

H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress - Investing.com

Aug 10, 2026